ALFA Finder| Revenue growth | FY26 revenue up 12.3% to ₹1,875cr; H2 outperformed H1 by 21%. |
|---|---|
| Margins | Gross margins expanded 128bps to 68%; Q4 consolidated EBITDA at 21%. |
| Demand visibility | Strong domestic and international demand; visibility improving in US and Europe. |
| Management confidence | Confident but cautious regarding global geopolitical volatility and raw material inflation. |
Growth
FY26 consolidated revenue rose 12.3% to ₹1,875cr; H2 grew 21% over H1, meeting prior H2 guidance.
Outlook
FY27 revenue guidance is ₹2,300-₹2,400cr (22-28% growth); EBITDA margins guided at 23-25%.
Risks
Raw material costs surged 20% due to crude prices; geopolitical disruptions in Red Sea impact logistics.
Earnings Call filed with BSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,672.10
- Market cap
- ₹16,949 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 53.2×Sector 54.5×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Earnings Call Transcript: Key Takeaways
Consolidated Q2 revenue rose 31%, but H1 organic growth was only 14%. Pendra Care is loss-making and Italy tenders are delayed. FY27 revenue guidance was reaffirmed and the standalone margin band raised.
- Call
- Guides 100% growth
Poly Medicure Other Announcement
Poly Medicure's board revised five governance policies and codes, including material subsidiary, materiality, related party transactions, and insider trading codes. The revised documents are published on the company website.
Poly Medicure Q2 FY27 Results: Net Profit ₹95.1 Cr, Up 3.6% YoY
Poly Medicure Ltd reported revenue from operations of ₹580.5 Cr (+30.8% YoY) and net profit of ₹95.1 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹95.1 Cr · +3.6% YoY
Poly Medicure Board Meeting Date
Poly Medicure will hold a board meeting on 05 November 2026 to consider unaudited results. Trading window stays closed until 07 November 2026.
Poly Medicure Other Announcement
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.